LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sangamo Therapeutics, Inc...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) investors concerning the C...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) on behalf of investors concerning th...

U.S. stocks traded slightly lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday.

The small-cap won't receive an expected payout in the first quarter, creating a cash overhang.

Sangamo Therapeutics (SGMO) shares cratered more than 50% Tuesday, a day after the biopharma firm announced that Pfizer (PFE) had pulled out of its deal to co-develop a hemophilia drug.

On Monday, Sangamo Therapeutics, Inc. SGMO regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe...

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Tuesday.

Sangamo stock crashes 60.4% as partner Pfizer decides to end collaboration for hemophilia A candidate, giroctocogene fitelparvovec.

Shares in Sangamo Therapeutics dropped 50% premarket after Pfizer Inc (NYSE:PFE, ETR:PFE) ended its collaboration on a gene therapy for haemophilia The drug, giroctocogene fitelparvovec, met its targe...

Sangamo Therapeutics said on Monday it would regain full rights to its hemophilia A gene therapy after co-development partner Pfizer terminated the agreement.

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER'S DECISION TO CEASE DEVELOPMENT.

Sangamo Therapeutics, Inc. received IND clearance to initiate a phase 1/2 study for ST-503 targeting idiopathic small fiber neuropathy, a type of chronic neuropathic pain condition. SGMO entered a dea...

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ST-503 FOR THE TREATMENT OF IDIOPATHIC SMALL FIBER NEUROPATHY.

Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript

Sangamo Therapeutics (SGMO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.34 per share a year ago.

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES THIRD QUARTER 2024 CONFERENCE CALL AND WEBCAST.

Positive Type B meeting held with FDA, whereby U.S. agency stated that the phase 1/2 STAAR study using isaralgagene civaparvovec targeting Fabry Disease patients would be enough for Accelerated Approv...

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025.

Sangamo Therapeutics, Inc.'s stock surged after positive updates on two lead assets, giro-vec and STAC-BBB, with potential for significant milestone payments and partnerships. The upcoming isa-vec dea...